When to Pause a Child's Biologic Dose for Illness

Within hours, a parent is holding a pre-filled syringe, or staring at an oral prescription bottle on the kitchen counter, and asking the question that every pediatric immunology, rheumatology, and allergy clinic hears at least once a week: do we give today's dose, or do we hold it? This is the kind of decision that looks small on the calendar and enormous at the kitchen table.

Biologic therapies have transformed the management pathway for children with juvenile idiopathic arthritis, severe asthma, pediatric lupus, autoinflammatory syndromes, and refractory atopic disease. But these same agents work by damping specific arms of the immune cascade, and the moments when the immune system actually needs to mount a full response — during an active infection — are exactly the moments when dampening carries its clearest risk. The clinical consensus is clear, but the day-to-day execution is nuanced, and the gap between the consensus and the kitchen counter is where most of the practical questions live.

Clinical Triggers for Holding Biologic Doses in Children

The first thing we anchor to, both in clinic and in our written guidance to families, is the concept of an active, acute, or febrile infection. When a child on a biologic presents with a fever — for our purposes, a temperature at or above 38.0°C (100.4°F) measured by a reliable route, or any febrile illness of uncertain origin — the standard recommendation across pediatric rheumatology, dermatology, allergy-immunology, and gastroenterology is to temporarily withhold the next scheduled dose until the infection has been identified, characterized, and treated appropriately.

This is not a suggestion born of caution alone. Biologic response modifiers — whether they are TNF-α inhibitors such as etanercept and adalimumab, IL-1 or IL-6 blockers such as anakinra and tocilizumab, B-cell–depleting agents such as rituximab, or the newer agents targeting the JAK pathway — all carry a measurable increase in the rate of serious and opportunistic infections, and that risk rises during any window where the underlying disease is active and the immune system is simultaneously being suppressed. Holding a dose during an acute infection is the standard protective maneuver, and it is the maneuver we expect the family and the primary care team to coordinate together rather than improvise alone.

The trigger list we rehearse with every family at the start of therapy covers several overlapping categories: documented or suspected bacterial infection requiring antibiotics (especially respiratory, urinary, skin and soft tissue, or oropharyngeal); any febrile viral illness including influenza, RSV, COVID-19, or undifferentiated viral syndromes with fever; active localized infection of meaningful severity such as cellulitis, an abscess, an infected eczema flare, or a dental abscess; suspected or confirmed opportunistic infection; and recent close contact with a communicable illness that carries a high complication rate in immunocompromised children, such as varicella exposure without prior immunity, measles, or tuberculosis. Each of these shifts the balance toward a hold.

Differentiating Mild Symptoms from Acute Febrile Illnesses

Here is where the conversation tends to slow down, because real children are not case studies. A biologic dose is scheduled for Tuesday, and on Monday night the child has the sniffles. Or there is a tiny scratch on the shin that looks pink. Or a mild headache follows a long day at school. We want to be precise about what actually triggers a hold, because frequent unnecessary holds erode disease control and quality of life just as surely as missed doses during a true infection.

The clinical presentation that warrants a hold shares three features: there is a measured fever, there is a clear infectious focus, or there is a symptom complex — vomiting, lethargy, painful swallowing, productive cough, dysuria, photophobia — severe enough that the family and the clinician together suspect a bacterial or systemic process. A child with mild upper respiratory congestion and no fever, who is eating, drinking, and playing at their baseline, can usually receive the scheduled dose on time after a quick check-in with the primary care office. This is where the practical pathway matters most, because most specialists do not want every mild symptom to result in a held dose. The diseases being treated — juvenile idiopathic arthritis, severe asthma, pediatric lupus, autoinflammatory fever syndromes — flare quickly when control is interrupted, and an overcautious hold pattern produces its own measurable harm.

What we ask families to do, and what we rehearse at every clinic visit, is to run a brief triage before each scheduled dose. Is there a measured fever, or has there been one in the past 24 hours? Is there any new localized pain, swelling, redness, or discharge? Has the child been around anyone with a confirmed serious infection — strep pharyngitis, influenza, COVID-19, varicella? Is the child otherwise behaving at their baseline — eating, drinking, voiding, and engaging in age-appropriate activity? If the answers are reassuring across all four, the dose proceeds. If any answer raises concern, the family calls the prescribing specialist or the primary care clinician before injecting.

The Role of Primary Care Triage and Diagnostic Testing

The pediatric primary care provider is, in most care pathways, the first clinician to evaluate a sick child on a biologic. This is a deliberate feature of the management structure, not an accident of geography. The rheumatologist or allergist who prescribes the biologic may be in a different city, on a different schedule, and unfamiliar with the local epidemiology of circulating infections. The primary care clinician knows the child's baseline, has the throat swab, the urine dipstick, the rapid strep test, the rapid influenza and RSV platforms, and the ability to examine the child in person.

What the primary care visit needs to accomplish, when a child on a biologic presents with possible infection, is three things. First, characterize the clinical presentation — is this a self-limiting viral upper respiratory infection, a bacterial process requiring antibiotics, or something more ambiguous that warrants observation and follow-up? Second, initiate empiric treatment when indicated, because delaying antibiotics while waiting for a specialist reply is rarely the right answer for a febrile child on an immunosuppressive agent. Third, communicate directly with the prescribing specialist about whether to hold the upcoming dose. This last point matters more than families often realize, because the decision to hold is rarely made by one clinician alone.

Holding a biologic during an active infection is the standard protective maneuver — but the decision belongs to the prescribing team, not the parent acting alone.

The primary care clinician provides the diagnostic picture; the prescribing specialist translates that picture into a dosing decision for the specific agent the child is receiving. A child on weekly methotrexate with a monthly infliximab infusion will be managed differently from a child on daily oral tofacitinib who completed a recent loading course of rituximab. The half-life of the drug, the mechanism of immunosuppression, the indication being treated, and the severity of the infection all feed into a decision that should not be rushed from a single phone call.

Antibiotic Completion and Safely Timing Treatment Resumption

Once an infection has been identified and treated, the question turns from holding to resuming. This is the part of the management pathway where families most often ask for a single clean number, and it is also the part where we have to be honest about the limits of a universal answer.

The general principle, articulated in the joint guidance published in 2022 on the management of interruption of biologic therapy, is that the biologic is resumed after the acute infection has clinically resolved and any prescribed antibiotic course has been completed. For a straightforward bacterial infection — a treated otitis media, a completed course of antibiotics for strep pharyngitis, a resolved urinary tract infection — most specialists will green-light resumption once the child is afebrile for at least 24 to 48 hours, symptoms are clearly improving, and the antibiotic course is finished. This is the most common scenario, and it is the one where the primary care clinician can often give direct guidance without waiting on the specialist.

For more complex infections, the timeline extends. A child recovering from influenza with secondary bacterial pneumonia will typically wait longer than a child recovering from an isolated streptococcal pharyngitis. A child with confirmed varicella, herpes zoster, or any deep tissue infection will be evaluated by the specialist individually. There is no single universal threshold — the resumption decision depends on the pathogen, the severity of the infection, the specific biologic, and the underlying disease being treated. This is one of the points where we counsel families explicitly: please do not extrapolate from one infection to the next, and please do not extrapolate from another child's experience to your own.

One point we want families to internalize is that permanently stopping or restarting a biologic on their own is never the right move. Disease flare-ups after unsupervised discontinuation are well documented in pediatric rheumatology and allergy practice, and the recovery — particularly after a long-acting agent like rituximab — can take longer than the family expects. Holding is a temporary maneuver. Stopping is a different decision entirely, and it belongs in the prescribing specialist's hands.

Preventative Infection Protocols and Vaccination Windows

The best hold is the one that never has to happen. Before a child starts a biologic in the first place, the prescribing team runs a defined preventative protocol that meaningfully reduces the number of infections the child will face while on therapy, and that protocol is worth understanding even when the question on the table is about pausing.

Vaccination timing relative to biologic initiation is one of the most actionable parts of this protocol. The recommendation, anchored in pediatric infectious disease and immunology consensus, is that live vaccines — including MMR, varicella, and live attenuated influenza — are administered at least four weeks before starting the biologic. Inactivated vaccines — including the inactivated influenza shot, COVID-19 vaccines, hepatitis B, HPV, and the routine pediatric schedule vaccines — are administered at least two weeks before the first dose. This timing allows the immune response to the vaccine to mature before immunosuppression begins, and it is the reason the vaccine history review is one of the very first things we do in clinic.

Vaccination timing is a one-time planning opportunity — a four-week window for live vaccines, a two-week window for inactivated vaccines — that is far easier to use before the biologic starts than to recreate afterwards.

Once a child is already on a biologic, the vaccine conversation continues but the rules shift. Inactivated vaccines can usually be administered on schedule, because they do not carry a risk of vaccine-strain infection. Live vaccines are a different matter and require a coordinated decision between the family, the primary care clinician, and the prescribing specialist — typically involving a planned hold of the biologic around the time of live vaccine administration. We do not administer live vaccines to a child who is actively on an immunosuppressive biologic without that coordination, and we do not rely on parental recall alone to confirm which vaccines have been given.

Screening for latent infections is the second pillar of the preventative protocol. Before initiating biologic response modifiers that carry a known risk of reactivating latent viral infections — most prominently rituximab and the anti–TNF-α inhibitors — clinicians routinely check hepatitis B surface antigen, surface antibody, and core antibody, and consider hepatitis C and HIV screening. A child with evidence of prior hepatitis B exposure who starts rituximab without appropriate antiviral prophylaxis is at meaningful risk of reactivation, and we have moved this from a specialist-level consideration to a routine pre-initiation checklist item.

Closing

When we step back from the immediate question — hold or give today — what we are really managing is the long-term balance between immune suppression and immune competence. A child on a biologic has had that balance deliberately shifted, and every febrile illness is a small referendum on whether the shift is appropriate for that moment. Holding during an active infection is the standard protective practice; resuming once the infection has resolved and antibiotics are completed is the standard return to baseline. The two decisions are not symmetric. Holding protects, but extending a hold longer than necessary loses disease control and quality of life. That asymmetry is why we keep the decision in the hands of the prescribing team, anchored by what the primary care clinician sees on the ground.

For families, the practical pathway is short. When a scheduled dose is approaching and the child is sick, call the primary care office. When the primary care office identifies an active infection that warrants treatment, they will coordinate with the prescribing specialist. When the infection has resolved and the antibiotic course is complete, the specialist will confirm resumption. The hardest part of this pathway, in our experience, is the waiting. The second hardest part is resisting the urge to make the decision alone, because the disease being treated did not become serious enough to warrant a biologic without good reason, and the protection it provides is worth protecting in turn.